NTS Ventures and IHMA Announce a Collaborative Agreement to Provide an Extensive Suite of Clinical Mycology, Antifungal and Microbiology Laboratory Services to Support Anti-infective Drug Developme...
SCHAUMBURG, Ill., Dec. 04, 2017 (GLOBE NEWSWIRE) -- NTS Ventures (NTS), a mycology and antifungal clinical research laboratory and International Health Management Associates, Inc./IHMA Europe Sàrl (IHMA), a full-service central clinical microbiology laboratory have announced a non-exclusive collaborative agreement that will provide the pharmaceutical industry with an extensive suite of mycology and antifungal testing services and microbiology testing services, including specialties in antibacterial agents and biofilms. The suite of services includes pre-clinical in vitro and in vivo antifungal services, mechanism of action investigations, full antifungal clinical trial services and regulatory services as well as microbiology support for clinical and surveillance studies and specialty testing studies.
The development of new anti-infectives has increased rapidly over the past ten years. The need to support these important, life-saving products has increased as well. The agreement between NTS and IHMA will allow all pharmaceutical and biotech companies access to mycological, antifungal and microbiology clinical laboratory testing that is required to develop and support antifungal and antimicrobial drugs. Both NTS and IHMA employ highly qualified and experienced clinical microbiologists and scientists with expertise in anti-infectives. With this collaboration, IHMA and NTS will be able to offer an extensive suite of mycology and antifungal testing services in addition to its existing all-encompassing suite of antibacterial services.
"This collaborative partnership integrating the outstanding capabilities at both IHMA and NTS creates a single destination for antimicrobial drug development, creating an incredibly efficient and expedient resource for the biopharmaceutical industry," said Dr. Mahmoud Ghannoum, Founder of NTS Ventures.
"IHMA is very excited about this new relationship with NTS Ventures. This opportunity gives both organizations the ability to better support the biopharmaceutical industry's goals to develop new and more potent antifungal and antibacterial agents," said Dr. Daniel Sahm, Chief Scientific Officer and VP of Global Microbiology Services at IHMA, Inc.
ABOUT NTS Ventures
NTS is based in Cleveland, OH and provides preclinical, clinical and translational services designed to bring antifungal, antibacterial and dermatology agents from discovery to market. NTS has the ability to support drug development in preclinical and clinical testing phases in order to satisfy FDA Investigational New Drug (IND) and New Drug Application (NDA) submissions. Over the past 25 years the NTS team has worked with a large range of entities including global Big Pharma, start up and growth stage biotech companies, full-spectrum CRO's as well as academic institutions.
For more information, please visit https://www.ntsventures.com.
IHMA is based in Schaumburg, IL USA and Monthey, Switzerland and has been a premier provider of antimicrobial drug development services over the past 25 years. Our laboratory facilities in both the US and Europe partner with clients around the world in the biotechnology, pharmaceutical, and diagnostic industries. IHMA is a leading, independent laboratory specializing in surveillance studies and clinical trials, key milestones along the continuum from drug development to commercialization. IHMA utilizes state of the art technology, leading to first-class testing and data as well as sound economic frameworks. IHMA's services can be customized to best align with its clients' unique testing needs. This ensures successful drug development, commercialization, and post-marketing pathways.
For more information, visit the IHMA website at: www.ihma.com
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: IHMA Inc via Globenewswire
Följ NASDAQ OMX
Abonnera på våra pressmeddelanden.
Senaste pressmeddelandena från NASDAQ OMX
Momentum Group förvärvar Reklamproffsen i Örebro20.3.2018 08:45 | Pressmeddelande
Momentum Group AB (publ) har förvärvat 70 procent av aktierna i Reklamproffsen Skandinavien AB ("Reklamproffsen"). Reklamproffsen är en ledande återförsäljare av produktmedia innefattande yrkeskläder och profilkläder i Örebro med omnejd. Reklamproffsen omsätter cirka 35 MSEK per år med god lönsamhet och har 12 anställda. Reklamproffsen är en av Örebros största återförsäljare inom yrkeskläder och profilkläder med hög kompetens inom företagsprofilering. Reklamproffsen har en yrkesbutik och utställning i Örebro. Kunderna utgörs främst av industri- och serviceföretag och en betydande andel av försäljningen sker via kundunika webbshoppar. - Reklamproffsen har med sina starka kund- och leverantörsrelationer och medarbetare med hög kompetens utvecklats framgångsrikt ända sedan starten år 2000. Bolaget är idag ett väletablerat företag i Örebro med omnejd. Vi ser mycket goda möjligheter till vidare utveckling och tillväxt för Reklamproffsen som en del av Momentum Group, säger Ulf Lilius, VD & K
Momentum Group acquires Reklamproffsen in Örebro20.3.2018 08:45 | Pressmeddelande
Momentum Group AB (publ) has acquired 70 percent of the shares in Reklamproffsen Skandinavien AB ("Reklamproffsen"). Reklamproffsen is a leading reseller of promotional products, including workwear and profile clothing, in Örebro and the surrounding area. Reklamproffsen generates annual revenue of approximately MSEK 35 with favourable profitability and has 12 employees. Reklamproffsen is one of Örebro's largest resellers of workwear and profile clothing, with a high level of expertise in customising company products. Reklamproffsen has a professional store and showroom in Örebro. Its customers mainly comprise industrial and service companies, and a significant portion of its sales are conducted via customised online stores. "Thanks to its strong customer and supplier relationships and highly skilled employees, Reklamproffsen has achieved successful growth since it was formed in 2000. It is now a well-established company in Örebro and the surrounding area. We anticipate good opportuniti
Immunicum AB: Immunicum AB (publ) meddelar att ilixadencel har beviljats ATMP-certifiering från EMA gällande tillverkningskvalitet och prekliniska data20.3.2018 08:00 | Pressmeddelande
Pressmeddelande 20 mars 2018 Immunicum AB (publ) meddelar att ilixadencel har beviljats ATMP-certifiering från EMA gällande tillverkningskvalitet och prekliniska data Immunicum AB (publ; IMMU.ST) ett bioteknikbolag som utvecklar nya immunostimulerande cancerbehandlingar för ett antal solida tumörformer, meddelar idag att bolagets ledande produktkandidat, ilixadencel, har erhållit en ATMP-certifiering (Advanced Therapy Medicinal Product) efter granskning av tillverkningskvalitet och prekliniska data av den europeiska läkemedelsmyndigheten EMA (European Medicines Agency). "EMAs ATMP certifikat är en viktig milstolpe i utvecklingen av ilixadencel eftersom det validerar vår tillverkningskvalitet och våra prekliniska data, och ger oss samtidigt en solid bas för de senare faserna i den kliniska utvecklingen. Cell-baserade terapier måste uppfylla mycket höga krav och vi är glada att få detta erkännande av EMA för vårt arbete så här långt," säger Carlos de Sousa, VD för Immunicum. "Immunicum ä
Immunicum AB: Immunicum AB (publ) Announces ATMP Certificate Granted by EMA to Ilixadencel for Manufacturing Quality and Non-clinical Data20.3.2018 08:00 | Pressmeddelande
Press Release 20 March 2018 Immunicum AB (publ) Announces ATMP Certificate Granted by EMA to Ilixadencel for Manufacturing Quality and Non-clinical Data Immunicum AB (publ; IMMU.ST) a biopharmaceutical company advancing a novel, immune-priming cancer treatment against a variety of solid tumors, announced today that its lead product candidate, ilixadencel, has been granted an Advanced Therapy Medicinal Product (ATMP) certificate following a review of manufacturing quality and non-clinical data by the European Medicines Agency (EMA). "The EMA ATMP certificate is an important development milestone for ilixadencel because it validates our manufacturing quality and preclinical data and gives us a firm foundation for the later stages of clinical development. Cell-based therapies must meet very high requirements and we are pleased to have this recognition from the EMA of our work to date," said Carlos de Sousa, CEO of Immunicum. "Immunicum is one of very few companies that have successfully u
Nitinat Provides Update on the Carscallen Gold Property19.3.2018 21:30 | Pressmeddelande
TORONTO, March 19, 2018 (GLOBE NEWSWIRE) -- Further to its press release dated March 12, 2018 whereby Nitinat Minerals Corp. (the "Corporation") (TSX-V:NZZ) (Frankfurt:04U1) announced its option to acquire four (4) additional claims (collectively, the "Claims") abutting the western boundaries of the Corporation's current mining claims in Carscallen Township, Ontario (the "Carscallen Gold Property"), the Corporation is pleased to provide additional information pertaining to the Claims. The Corporation intends to implement an exploration program for the Claims to fully explore the potential of the Claims. The "preliminary technical appraisal" provided herein, along with the geophysics that the Corporation intends to undertake, will identify potential drill targets. The property encompassing the Claims is of particular interest in that surface exploration to date on the Claims has shown the existence of historic surface mining and sampling. The Corporation is currently assessing the most
New Elemica Trace Solution Delivers Shipment Risk Analysis for Digital Transformation19.3.2018 13:09 | Pressmeddelande
Real-Time Information Matched with GPS Locations Provides Accurate Delivery Information WAYNE, Pa., March 19, 2018 (GLOBE NEWSWIRE) -- Elemica, the leading Digital Supply Network for process manufacturing industries, introduces Elemica Trace, a solution that provides real-time shipment and risk visibility to customer service, transport planners, and supply chain managers, allowing them to monitor and proactively manage the movement of products to customers and inbound to manufacturing centers. "Shipment disruptions occur and teams can spend hours manually tracking down what is happening. What's worse, sometimes your customer complaint is the first indication you have of a late shipment," said Rich Katz, CTO of Elemica. "Trace eliminates the time and stress of tracking shipments and enables your teams to increase the positive interactions with your customers." Elemica Trace uses shipment data, carrier signals, a geo-location interface, and predictive algorithms to identify shipments in
I vårt pressrum kan du läsa de senaste pressmeddelandena, få tillgång till pressmaterial och hitta kontaktinformation.Besök vårt pressrum